F M Investments LLC Acquires Shares of 47,794 Soleno Therapeutics, Inc. (NASDAQ:SLNO)

F M Investments LLC bought a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 47,794 shares of the company’s stock, valued at approximately $2,148,000.

A number of other institutional investors also recently modified their holdings of the company. Barclays PLC raised its position in Soleno Therapeutics by 149.3% during the 3rd quarter. Barclays PLC now owns 52,545 shares of the company’s stock valued at $2,652,000 after purchasing an additional 31,467 shares during the last quarter. Emerald Advisers LLC increased its stake in shares of Soleno Therapeutics by 85.4% during the fourth quarter. Emerald Advisers LLC now owns 580,919 shares of the company’s stock valued at $26,112,000 after buying an additional 267,585 shares during the period. State Street Corp raised its holdings in shares of Soleno Therapeutics by 14.2% during the third quarter. State Street Corp now owns 1,142,169 shares of the company’s stock valued at $57,668,000 after acquiring an additional 142,033 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Soleno Therapeutics by 13.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company’s stock worth $9,779,000 after acquiring an additional 24,953 shares during the period. Finally, Sei Investments Co. boosted its holdings in Soleno Therapeutics by 47.0% in the fourth quarter. Sei Investments Co. now owns 16,444 shares of the company’s stock valued at $739,000 after acquiring an additional 5,258 shares in the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SLNO has been the subject of several research reports. Robert W. Baird upped their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, March 27th. Stifel Nicolaus increased their price target on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, March 28th. Cantor Fitzgerald raised their price objective on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Lifesci Capital upgraded Soleno Therapeutics to a “strong-buy” rating in a report on Tuesday, February 4th. Finally, Laidlaw raised their target price on Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $99.63.

Insiders Place Their Bets

In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 699,095 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares of the company’s stock, valued at approximately $39,021,879.12. The trade was a 54.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Michael F. Huang sold 14,583 shares of the stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $69.51, for a total value of $1,013,664.33. Following the transaction, the vice president now directly owns 36,817 shares in the company, valued at $2,559,149.67. The trade was a 28.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 942,672 shares of company stock valued at $64,058,781. 12.30% of the stock is owned by insiders.

Soleno Therapeutics Stock Up 6.9 %

Shares of NASDAQ SLNO opened at $67.23 on Friday. The firm has a market cap of $3.08 billion, a P/E ratio of -20.25 and a beta of -2.29. Soleno Therapeutics, Inc. has a twelve month low of $36.61 and a twelve month high of $74.00. The company has a 50 day moving average of $53.20 and a 200 day moving average of $51.38.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.41). As a group, equities analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.